Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies
- 30 June 2019
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 39 (7), 3917-3921
- https://doi.org/10.21873/anticanres.13543
Abstract
Aim: To evaluate the efficacy and safety of re-treatment with anti-programmed death (PD)-L1 antibody (atezolizumab) after anti-PD-1 antibody (nivolumab/pembrolizumab) treatment in advanced non-small cell lung cancer (NSCLC) patients. Patients and Methods: We retrospectively reviewed 18 NSCLC patients who received atezolizumab after anti-PD-1 antibody treatment. Data on patient characteristics, number of cycles of anti-PD-1 antibody and atezolizumab, regimens between anti-PD-1 antibody and atezolizumab, best response, and immune-related adverse events (irAEs) were collected and analyzed. Results: Nine patients a had high (>= 50%) PD-L1 expression. The median number of cycles of atezolizumab was 3 (range=2-7). The median progression-free survival was 2.9 +/- 1.8 months. Seven (38.9%) and 11 (61.1%) patients had stable and progressive disease, respectively. No patient achieved partial or complete response. There were no significant differences in the occurrence of irAEs between anti-PD-1 antibodies and atezolizumab. Conclusion: Preliminary results showed that patients previously treated with anti PD-1 antibodies received only limited benefit from subsequent atezolizumab.Keywords
This publication has 13 references indexed in Scilit:
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progressionEuropean Journal Of Cancer, 2018
- Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancerOncotarget, 2018
- Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 casesCancer Chemotherapy and Pharmacology, 2018
- Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumabCancer Chemotherapy and Pharmacology, 2017
- Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanomaMelanoma Research, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Combination cancer immunotherapy and new immunomodulatory targetsNature Reviews Drug Discovery, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015